TABLE 4.
Highlights current clinical trials of the use of MSCs in cell therapy applications.
| Clinical trial identifier | MSCs source | Title | Objective | Phase | Status | Trial duration | Country |
|---|---|---|---|---|---|---|---|
| NCT04318600 | Human Amniotic Mesenchymal stem cell (HA-MSC) | Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis | To evaluate the safety and efficacy of human amniotic mesenchymal stem cells (hA-MSC) for the treatment of lupus nephritis (LN) | Phase 1 | Completed | 01 January 2014–01 January2019 | N/A |
| NCT03333681 | Mesenchymal stem cells | Evaluation of the effects of stem cell therapy on the immune response in Rheumatoid Arthritis Patients | Evaluation of the effects of mesenchymal stem cell therapy on cellular and humoral immune responses in patients with refractory rheumatoid arthritis (RA) patients | Phase 1 | Completed | 20 June 2016–15 September 2018 | N/A |
| NCT03343782 | Bone Marrow-derived Mesenchymal Stem Cells | Outcomes of expanded autologous bone marrow-derived mesenchymal stem cell therapy in Type II Diabetes (ASD2) | To evaluate the safety and effectiveness of autologous bone marrow-derived mesenchymal stem cell transplantation in the treatment of patients with type 2 diabetes mellitus | Phase 1and 2 | Completed | 01 November 2017–01 August 2019 | Vinmec International Hospital, Hanoi, Vietnam |
| NCT02181712 | Bone Marrow-derived Mesenchymal stem cells | Mesenchymal stem cell therapy for Lung Rejection | To assess the safety and feasibility of mesenchymal stem cell therapy in patients with transplant-related bronchiolitis obliterans syndrome (BOS) | Phase 1 | Completed | July 2014–12 August 2021 | Florida, United States |
| NCT03326505 | Umbilical Cord derived Mesenchymal Stem Cells (MSCs) | Allogenic Mesenchymal Stem Cells and Physical Therapy for MS Treatment | To study the effect of UC-MSCs in Multiple Sclerosis and comprehensive supervised physical therapy | N/A | Completed | 25 September 2017–25 January 2020 | Jordan |
| NCT04713878 | Mesenchymal stem cells | Mesenchymal stem cell therapy in patients with COVID-19 Pneumonia | Assess the effect of MSCs in providing an immune response and repairing the damaged organs | N/A | Completed | 08 May 2020–30 June 2020 | University of Health Sciences Istanbul, Turkey |
| NCT01809769 | Adipose Tissue Derived Mesenchymal Stem Cells | Autologous adipose tissue-derived mesenchymal stem cell therapy for patients with Knee Osteoarthritis | To evaluate the effects of AD-MSCs in patients with knee osteoarthritis | Phase 1and2 | Completed | March 2013- March 2015 | Shanghai, China |
| NCT02611167 | Mesenchymal stem cells | Allogenic bone marrow-derived mesenchymal stem cell therapy for Idiopathic Parkinson’s Disease | To evaluate the safety, feasibility, and efficacy of intravenous allogeneic bone marrow-derived mesenchymal stem cell therapy (MSC) for idiopathic Parkinson’s disease (iPD) | Phase 1 | Completed | 01 November 2017–18 September 2019 | United States |
| NCT02192749 | Allogeneic Umbilical Cord Mesenchymal stem cell | Allogeneic umbilical cord mesenchymal stem cell therapy for Autism | Assess the safety, feasibility, and efficacy of human umbilical cord tissue-derived stem cells that will induce a therapeutic effect in autism patients | Phase 1and2 | Completed | July 2014- August 2017 | Stem Cell Institute |
| Panama City, Panama |